Neoadjuvant chemoradiation
Showing 1 - 25 of 3,677
Gastroesophageal Junction Adenocarcinoma Trial in Beijing (Serplulimab)
Recruiting
- Gastroesophageal Junction Adenocarcinoma
-
Beijing, ChinaPeking Union Medical College Hospital
Jun 15, 2023
Neoadjuvant Chemoradiation Therapy, Rectal Cancer, Immunotherapy Trial in Shanghai (xintilimab injection, Control)
Recruiting
- Neoadjuvant Chemoradiation Therapy
- +3 more
- xintilimab injection
- Control
-
Shanghai, Shanghai, ChinaDepartment of Colorectal Surgery in Changhai Hospital
Aug 5, 2022
Oncology Trial in Nijmegen (combined aerobic exercise + resistance exercise intervention (AE + RE), Aerobic exercise prior to
Recruiting
- Oncology
- combined aerobic exercise + resistance exercise intervention (AE + RE)
- Aerobic exercise prior to daily radiotherapy sessions (ExPR)
-
Nijmegen, Gelderland, NetherlandsRadboud Institute for Health Science
Jan 8, 2023
Stage IIIA NSCLC Trial in Cleveland (Cisplatin, Etoposide, Pembrolizumab)
Terminated
- Stage IIIA Non-Small Cell Lung Cancer
- Cisplatin
- +3 more
-
Cleveland, OhioCleveland Clinic Taussig Cancer Institute, Case Comprehensive Ca
Dec 15, 2022
Esophageal Carcinoma, Neoadjuvant Chemoradiotherapy, Surgery Trial in Hangzhou (Higher dose (50.4Gy/28F) of neoadjuvant
Recruiting
- Esophageal Carcinoma
- +2 more
- Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation
- Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation
-
Hangzhou, Zhejiang, China
- +1 more
Mar 12, 2022
Rectal Cancer Trial in Alexandria (radiation, drug, procedure)
Completed
- Rectal Cancer
- Radiotherapy
- +2 more
-
Alexandria, EgyptAhmed Samir Ashoor
Mar 7, 2022
Glioblastoma, Surgery, High Grade Glioma Trial in Danville, Wilkes-Barre (radiation, drug, procedure)
Recruiting
- Glioblastoma
- +2 more
- Neoadjuvant chemoradiation
- +2 more
-
Danville, Pennsylvania
- +1 more
Jan 24, 2022
Rectal Cancer Trial in Taipei (Surgery)
Recruiting
- Rectal Cancer
- Surgery
-
Taipei, TaiwanJin-Tung LIANG
Jul 27, 2023
Tumor, Rectum Trial (Total mesorectal excision before 56 days (4-8 weeks), Total mesorectal excision after 56 days (8-12 weeks))
Completed
- Neoplasm, Rectum
- Total mesorectal excision before 56 days (4-8 weeks)
- Total mesorectal excision after 56 days (8-12 weeks)
- (no location specified)
Mar 22, 2022
Locally Advanced Vulvar Carcinoma, Squamous Cell Carcinoma of the Vulva Trial (Paclitaxel and Carboplatin, Chemoradiation)
Not yet recruiting
- Locally Advanced Vulvar Carcinoma
- Squamous Cell Carcinoma of the Vulva
- Paclitaxel and Carboplatin
- Chemoradiation
- (no location specified)
Jun 6, 2023
Neoadjuvant Chemoradiation & Transplant for Cholangiocarcinoma
Recruiting
- Cholangiocarcinoma
- Observation data collection study.
-
Saint Louis, MissouriWashington University School of Medicine
Jul 28, 2022
Esophageal Adenocarcinoma (UICC TNM7), Adenocarcinoma of the Esophagogastric Junction Trial in Germany (5-Fluorouracil,
Active, not recruiting
- Esophageal Adenocarcinoma (UICC TNM7)
- Adenocarcinoma of the Esophagogastric Junction
- 5-Fluorouracil
- +6 more
-
Aachen, Germany
- +29 more
Nov 1, 2022
Rectal Cancer Trial in Shanghai (dosimetric limitation of pelvic bone and peritoneal space during radiotherapy)
Active, not recruiting
- Rectal Cancer
- dosimetric limitation of pelvic bone and peritoneal space during radiotherapy
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Jan 8, 2023
Esophageal Cancer, Esophageal Adenocarcinoma Trial in Amsterdam (Trastuzumab, Pertuzumab, Paclitaxel)
Recruiting
- Esophageal Cancer
- Esophageal Adenocarcinoma
- Trastuzumab
- +3 more
-
Amsterdam, NetherlandsAcademic Medical Center
Jun 18, 2022
Gastric Adenocarcinoma, Pancreatic Adenocarcinoma Trial in Houston (Aerobic Exercise, Dietary Intervention, Nutritional
Withdrawn
- Gastric Adenocarcinoma
- Pancreatic Adenocarcinoma
- Aerobic Exercise
- +5 more
- (no location specified)
Oct 26, 2022
Locally Advanced Rectal Cancer Trial in Beijing (Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course
Recruiting
- Locally Advanced Rectal Cancer
- Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
- Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
-
Beijing, Beijing, ChinaBeijing Friendship Hospital, Capital Medical University
Apr 25, 2023
Cervical Cancer, Neoadjuvant Chemo, Bulky Tumor Trial in Guangzhou (Albumin-Bound Paclitaxel, Carboplatin)
Recruiting
- Cervical Cancer
- +2 more
- Albumin-Bound Paclitaxel
- Carboplatin
-
Guangzhou, Guangdone, ChinaSun Yat-sen University Cancer Center
May 9, 2022
Adenocarcinoma Esophagus, Adenocarcinoma of the Gastroesophageal Junction Trial in Colorado Springs, Lone Tree (Sequential FLOT
Recruiting
- Adenocarcinoma Esophagus
- Adenocarcinoma of the Gastroesophageal Junction
- Sequential FLOT followed by chemoradiation
-
Colorado Springs, Colorado
- +2 more
Feb 22, 2022
Stage III Non-small-cell Lung Cancer Trial in Foshan, Guangzhou (other, radiation, drug)
Recruiting
- Stage III Non-small-cell Lung Cancer
- Neoadjuvant therapy
- +4 more
-
Foshan, Guangdong, China
- +2 more
Oct 25, 2022
Rectal Cancer Stage III Trial in Hangzhou (Neoadjuvant chemoradiotherapy based on irinotecan)
Recruiting
- Rectal Cancer Stage III
- Neoadjuvant chemoradiotherapy based on irinotecan
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Dec 7, 2021
Stage III NSCLC Trial in Guangzhou (Neoadjuvant chemo-immunotherapy, Bevacizumab, Radiotherapy)
Recruiting
- Stage III Non-small Cell Lung Cancer
- Neoadjuvant chemo-immunotherapy
- +5 more
-
Guangzhou, ChinaSun Yat-sen University
Jul 19, 2022
Larynx Cancer, Hypopharyngeal Cancer Trial in Shanghai (procedure, radiation, drug)
Recruiting
- Larynx Cancer
- Hypopharyngeal Cancer
- Surgery
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Sep 9, 2023
Cervical Cancer Trial in Chengdu (NACT, CCRT, Brachytherapy)
Not yet recruiting
- Cervical Cancer
- NACT
- +2 more
-
Chengdu, Sichuan, ChinaSicchuan cancer hospital
Dec 28, 2021
A PILOT STUDY OF DIFFUSION WEIGHTED MRI TO ASSESS ESOPHAGEAL
Completed
- Esophageal Cancer
- Chemotherapy
- +4 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Apr 23, 2021